Skip to main content
Erschienen in: Endocrine 1/2024

26.12.2023 | Review

The prevalence of positive thyroid autoantibodies in patients with subacute thyroiditis: a systematic review and meta-analysis

verfasst von: Arman Shekarian, Mohammad Fakhrolmobasheri, Sadegh Mazaheri-Tehrani, Amirhossein Yousefian, Maryam Heidarpour

Erschienen in: Endocrine | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Abstract

Purpose:

Subacute thyroiditis (SAT) is a transient inflammatory disorder of the thyroid gland with a possible viral etiology. We conducted this study to estimate the pooled prevalence of thyroid autoantibodies in SAT patients. This question arose due to the varying reports on the positivity rates of thyroid autoantibodies among SAT patients.

Methods:

We searched PubMed, Embase, Scopus, and Web of Science from their inception until March 25th, 2023. Observational studies reporting the positivity rate of thyroid autoantibodies for more than ten patients were included. We used the Joanna Briggs Institute’s (JBI) critical appraisal checklist to assess the quality of the included studies. Pooled prevalence estimates with 95% confidence intervals were calculated using the random effects model. Subgroup analyses were performed to find sources of heterogeneity.

Results:

Out of 1373 identified records, 32 studies involving 2348 SAT patients were included in our study. Thyroglobulin antibody (TgAb) and thyroid peroxidase antibody (TPOAb) were positive in 22.8% and 12.2% of patients, respectively. The Study design, mean erythrocyte sedimentation rate and mean thyroid-stimulating hormone of patients were identified as sources of heterogeneity. As our secondary objectives, we found a recurrence rate of 14.7% and permanent hypothyroidism in 11.6% of patients.

Conclusion:

The results of our study revealed a low TPOAb positivity rate in SAT patients, consistent with its non-autoimmune etiology. The TgAb positivity rate in SAT patients was higher than that of the general population, possibly explained by the transient release of thyroglobulin into the bloodstream during the thyrotoxic phase, leading to subsequent TgAb production. Furthermore, our findings demonstrate a notable recurrence rate and permanent hypothyroidism among SAT patients, highlighting the importance of ongoing follow-up care.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
2.
Zurück zum Zitat N. Erdem, M. Erdogan, M. Ozbek, M. Karadeniz, S. Cetinkalp, A.G. Ozgen, F. Saygili, C. Yilmaz, M. Tuzun, T. Kabalak, Demographic and clinical features of patients with subacute thyroiditis: results of 169 patients from a single university center in Turkey. J. Endocrinol. Invest. 30, 546–550 (2007). https://doi.org/10.1007/BF03346347CrossRefPubMed N. Erdem, M. Erdogan, M. Ozbek, M. Karadeniz, S. Cetinkalp, A.G. Ozgen, F. Saygili, C. Yilmaz, M. Tuzun, T. Kabalak, Demographic and clinical features of patients with subacute thyroiditis: results of 169 patients from a single university center in Turkey. J. Endocrinol. Invest. 30, 546–550 (2007). https://​doi.​org/​10.​1007/​BF03346347CrossRefPubMed
9.
17.
Zurück zum Zitat M.J. Page, J.E. McKenzie, P.M. Bossuyt, I. Boutron, T.C. Hoffmann, C.D. Mulrow, L. Shamseer, J.M. Tetzlaff, E.A. Akl, S.E. Brennan, R. Chou, J. Glanville, J.M. Grimshaw, A. Hróbjartsson, M.M. Lalu, T. Li, E.W. Loder, E. Mayo-Wilson, S. McDonald, L.A. McGuinness, L.A. Stewart, J. Thomas, A.C. Tricco, V.A. Welch, P. Whiting, D. Moher, The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372, n71 (2021). https://doi.org/10.1136/bmj.n71CrossRefPubMedPubMedCentral M.J. Page, J.E. McKenzie, P.M. Bossuyt, I. Boutron, T.C. Hoffmann, C.D. Mulrow, L. Shamseer, J.M. Tetzlaff, E.A. Akl, S.E. Brennan, R. Chou, J. Glanville, J.M. Grimshaw, A. Hróbjartsson, M.M. Lalu, T. Li, E.W. Loder, E. Mayo-Wilson, S. McDonald, L.A. McGuinness, L.A. Stewart, J. Thomas, A.C. Tricco, V.A. Welch, P. Whiting, D. Moher, The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372, n71 (2021). https://​doi.​org/​10.​1136/​bmj.​n71CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat C.B. Begg, M. Mazumdar, Operating characteristics of a rank correlation test for publication bias. Biometrics 50, 1088–1101 (1994)CrossRefPubMed C.B. Begg, M. Mazumdar, Operating characteristics of a rank correlation test for publication bias. Biometrics 50, 1088–1101 (1994)CrossRefPubMed
22.
Zurück zum Zitat J.G. Hollowell, N.W. Staehling, W.D. Flanders, W.H. Hannon, E.W. Gunter, C.A. Spencer, L.E. Braverman, Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J. Clin. Endocrinol Metab. 87, 489–499 (2002). https://doi.org/10.1210/jcem.87.2.8182CrossRefPubMed J.G. Hollowell, N.W. Staehling, W.D. Flanders, W.H. Hannon, E.W. Gunter, C.A. Spencer, L.E. Braverman, Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J. Clin. Endocrinol Metab. 87, 489–499 (2002). https://​doi.​org/​10.​1210/​jcem.​87.​2.​8182CrossRefPubMed
27.
Zurück zum Zitat C.A. Spencer, M. Takeuchi, M. Kazarosyan, C.C. Wang, R.B. Guttler, P.A. Singer, S. Fatemi, J.S. LoPresti, J.T. Nicoloff, Serum thyroglobulin autoantibodies: prevalence, influence on serum thyroglobulin measurement, and prognostic significance in patients with differentiated thyroid carcinoma. J. Clin. Endocrinol. Metab. 83, 1121–1127 (1998). https://doi.org/10.1210/jcem.83.4.4683CrossRefPubMed C.A. Spencer, M. Takeuchi, M. Kazarosyan, C.C. Wang, R.B. Guttler, P.A. Singer, S. Fatemi, J.S. LoPresti, J.T. Nicoloff, Serum thyroglobulin autoantibodies: prevalence, influence on serum thyroglobulin measurement, and prognostic significance in patients with differentiated thyroid carcinoma. J. Clin. Endocrinol. Metab. 83, 1121–1127 (1998). https://​doi.​org/​10.​1210/​jcem.​83.​4.​4683CrossRefPubMed
28.
Zurück zum Zitat Y. Li, D. Teng, Z. Shan, X. Teng, H. Guan, X. Yu, C. Fan, W. Chong, F. Yang, H. Dai, X. Gu, Y. Yu, J. Mao, D. Zhao, J. Li, Y. Chen, R. Yang, C. Li, W. Teng, Antithyroperoxidase and antithyroglobulin antibodies in a five-year follow-up survey of populations with different iodine intakes. J. Clin. Endocrinol. Metab. 93, 1751–1757 (2008). https://doi.org/10.1210/jc.2007-2368CrossRefPubMed Y. Li, D. Teng, Z. Shan, X. Teng, H. Guan, X. Yu, C. Fan, W. Chong, F. Yang, H. Dai, X. Gu, Y. Yu, J. Mao, D. Zhao, J. Li, Y. Chen, R. Yang, C. Li, W. Teng, Antithyroperoxidase and antithyroglobulin antibodies in a five-year follow-up survey of populations with different iodine intakes. J. Clin. Endocrinol. Metab. 93, 1751–1757 (2008). https://​doi.​org/​10.​1210/​jc.​2007-2368CrossRefPubMed
35.
Zurück zum Zitat D.S. Ross, H.B. Burch, D.S. Cooper, M.C. Greenlee, P. Laurberg, A.L. Maia, S.A. Rivkees, M. Samuels, J.A. Sosa, M.N. Stan, M.A. Walter, 2016 American thyroid association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid 26, 1343–1421 (2016). https://doi.org/10.1089/thy.2016.0229CrossRefPubMed D.S. Ross, H.B. Burch, D.S. Cooper, M.C. Greenlee, P. Laurberg, A.L. Maia, S.A. Rivkees, M. Samuels, J.A. Sosa, M.N. Stan, M.A. Walter, 2016 American thyroid association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid 26, 1343–1421 (2016). https://​doi.​org/​10.​1089/​thy.​2016.​0229CrossRefPubMed
38.
46.
Zurück zum Zitat K. Kamijo, H. Murayama, T. Uzu, K. Togashi, G.J. Kahaly, A novel bioreporter assay for thyrotropin receptor antibodies using a chimeric thyrotropin receptor (mc4) is more useful in differentiation of Graves’ disease from painless thyroiditis than conventional thyrotropin-stimulating antibody assay using porcine thyroid cells. Thyroid 20, 851–856 (2010). https://doi.org/10.1089/thy.2010.0059CrossRefPubMed K. Kamijo, H. Murayama, T. Uzu, K. Togashi, G.J. Kahaly, A novel bioreporter assay for thyrotropin receptor antibodies using a chimeric thyrotropin receptor (mc4) is more useful in differentiation of Graves’ disease from painless thyroiditis than conventional thyrotropin-stimulating antibody assay using porcine thyroid cells. Thyroid 20, 851–856 (2010). https://​doi.​org/​10.​1089/​thy.​2010.​0059CrossRefPubMed
50.
Zurück zum Zitat J. Yoshimura Noh, N. Miyazaki, K. Ito, K. Takeda, S. Hiramatsu, S. Morita, A. Miyauchi, T. Murakami, K. Inomata, S. Noguchi, T. Satoh, N. Amino, Evaluation of a new rapid and fully automated electrochemiluminescence immunoassay for thyrotropin receptor autoantibodies. Thyroid 18, 1157–1164 (2008). https://doi.org/10.1089/thy.2008.0119CrossRefPubMed J. Yoshimura Noh, N. Miyazaki, K. Ito, K. Takeda, S. Hiramatsu, S. Morita, A. Miyauchi, T. Murakami, K. Inomata, S. Noguchi, T. Satoh, N. Amino, Evaluation of a new rapid and fully automated electrochemiluminescence immunoassay for thyrotropin receptor autoantibodies. Thyroid 18, 1157–1164 (2008). https://​doi.​org/​10.​1089/​thy.​2008.​0119CrossRefPubMed
52.
Zurück zum Zitat M. Schott, D. Hermsen, M. Broecker-Preuss, M. Casati, J.C. Mas, A. Eckstein, D. Gassner, R. Golla, C. Graeber, J. van Helden, K. Inomata, J. Jarausch, J. Kratzsch, N. Miyazaki, M.A.N. Moreno, T. Murakami, H.J. Roth, W. Stock, J.Y. Noh, W.A. Scherbaum, K. Mann, Clinical value of the first automated TSH receptor autoantibody assay for the diagnosis of Graves’ disease (GD): an international multicentre trial. Clin. Endocrinol (Oxf) 71, 566–573 (2009). https://doi.org/10.1111/j.1365-2265.2008.03512.xCrossRefPubMed M. Schott, D. Hermsen, M. Broecker-Preuss, M. Casati, J.C. Mas, A. Eckstein, D. Gassner, R. Golla, C. Graeber, J. van Helden, K. Inomata, J. Jarausch, J. Kratzsch, N. Miyazaki, M.A.N. Moreno, T. Murakami, H.J. Roth, W. Stock, J.Y. Noh, W.A. Scherbaum, K. Mann, Clinical value of the first automated TSH receptor autoantibody assay for the diagnosis of Graves’ disease (GD): an international multicentre trial. Clin. Endocrinol (Oxf) 71, 566–573 (2009). https://​doi.​org/​10.​1111/​j.​1365-2265.​2008.​03512.​xCrossRefPubMed
54.
Zurück zum Zitat M. Stasiak, R. Michalak, B. Stasiak, A. Lewinski, Clinical characteristics of subacute thyroiditis is different than it used to be - current state based on 15 years own material. Neuro Endocrinol Lett. 39, 489–495 (2019)PubMed M. Stasiak, R. Michalak, B. Stasiak, A. Lewinski, Clinical characteristics of subacute thyroiditis is different than it used to be - current state based on 15 years own material. Neuro Endocrinol Lett. 39, 489–495 (2019)PubMed
Metadaten
Titel
The prevalence of positive thyroid autoantibodies in patients with subacute thyroiditis: a systematic review and meta-analysis
verfasst von
Arman Shekarian
Mohammad Fakhrolmobasheri
Sadegh Mazaheri-Tehrani
Amirhossein Yousefian
Maryam Heidarpour
Publikationsdatum
26.12.2023
Verlag
Springer US
Erschienen in
Endocrine / Ausgabe 1/2024
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-023-03655-6

Weitere Artikel der Ausgabe 1/2024

Endocrine 1/2024 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.